FRAXA’s mission is to find effective treatments and a cure for Fragile X by directly funding the most promising research. FRAXA’s research portfolio spans the spectrum of basic science, pre-clinical, and clinical research — all coordinated to make the most of each dollar. We maintain a diversified approach, developing several treatment strategies in parallel, since success is never certain in developing a single drug. We continue to fund research to define the precise defect in the Fragile X brain, because these basic studies may yield additional important therapeutic targets.
We fund approximately $1.5 million in postdoctoral fellowships and investigator-initiated program grants each year. The 2015 deadline is Monday Feb. 2. This section provides materials including:
FRAXA organizes and sponsors conferences where scientists share discoveries, plan collaborations, and bring new researchers into the field.
- FRAXA Investigators Meeting will NOT run in 2015 because the 2016 Gordon Conference would follow closely on its heels. Please attend the Gordon Conference!
- Gordon Conferences on Fragile X and Autism run alternate years (2016, 2018, etc.)
Resources available to researchers include a large array of FMR1 mutant mouse models. Details in this section.
- mutant mouse resource
- reagents, experimental compounds